Kineta Director Adds 237,500 Shares via Option Exercise Amid Merger
Kineta (KA) filed a Form 4 disclosing that director Shawn Iadonato exercised 237,500 stock options on 06/23/2025 at strike prices of $0.36 and $0.611, actions triggered by full vesting upon shareholder approval of the TuHURA Biosciences merger.
Rhea-AI Filing Summary
Kineta (KA) filed a Form 4 disclosing that director Shawn Iadonato exercised 237,500 stock options on 06/23/2025 at strike prices of $0.36 and $0.611, actions triggered by full vesting upon shareholder approval of the TuHURA Biosciences merger.
To cover taxes, 52,353 shares were sold at $0.26 (Code F). Net of the sale, his direct holdings rose to 860,377 shares; combined with 8,553 shares held via an IRA, total beneficial ownership is 868,930 shares, a ~27% increase.
The transactions were contractual (Code M) rather than open-market purchases, signalling alignment but offering limited insight into insider sentiment.
Positive
- Director’s direct ownership increased by 185,147 shares (net), a ~27 % rise, improving insider-shareholder alignment post-merger.
Negative
- A 52,353-share sale (≈6 % of newly issued shares) at $0.26 for tax withholding marginally offsets the ownership increase.
Insights
TL;DR: Option exercise lifts insider stake 27%, but merger-driven and neutral for valuation.
The bulk of the activity—225 k options at $0.36 and 12.5 k at $0.611—was automatically exercised once the TuHURA merger terms cleared, eliminating those options and adding 237.5 k shares to float. Only 52.4 k shares (≈6% of new shares) were sold for tax withholding, so most of the stock was retained, lifting Iadonato’s direct ownership to 860.4 k shares. While the 27% stake increase exceeds the 5 % materiality threshold for insider holdings, the lack of open-market buying tempers bullish interpretation. No cash proceeds to Kineta arise from the option exercise because strikes were minimal. Overall impact on share supply, governance control, and liquidity is modest, leaving the filing neutral for near-term valuation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 225,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,500 | $0.611 | $8K |
| Exercise | Common Stock | 225,000 | $0.36 | $81K |
| Exercise Price or Tax Liability | Common Stock | 52,353 | $0.26 | $14K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Shawn Iadonato's total beneficial ownership after the transactions?
Why did the options vest for Kineta’s director on 06/23/2025?
What were the exercise prices of the Kineta options exercised?
AI-generated analysis. How Rhea-AI works. Not financial advice.
